» Articles » PMID: 19578746

Chromosomally and Microsatellite Stable Colorectal Carcinomas Without the CpG Island Methylator Phenotype in a Molecular Classification

Overview
Journal Int J Oncol
Specialty Oncology
Date 2009 Jul 7
PMID 19578746
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

We hypothesized that in a comprehensive analysis of colorectal carcinomas (CRC) the three currently known major molecular mechanisms of carcinogenesis (i.e., chromosomal instability, microsatellite instability, and CpG island methylator phenotype, CIMP) would associate with the molecular features indicative of these pathways, allowing a molecular classification. A prospectively collected clinicopathologically well-characterized series of 130 CRCs was tested for chromosomal instability (DNA-flow cytometry and analysis of allelic imbalance with microsatellite markers 5q21, 8p21, 9q21, 17p13, and 18q21), microsatellite instability (Bethesda panel), CIMP (MethyLight), and mutations of K-ras, B-raf, APC, and p53. Morphology was reviewed, and nuclear beta-catenin translocation was assessed by immunohistochemistry. Based on the molecular features, sporadic high-degree microsatellite instable tumours, tumours of the hereditary non-polyposis coli carcinoma syndrome, and 'sporadic standard-type' CRC could be delineated (14, 4, and 55, respectively). However, overlap between classes was seen for 46 of the remaining tumours where widespread or occasional methylations (excluding MLH1) were observed, and the majority had chromosomal instability. Importantly, a group of 11 tumours was observed without either microsatellite or chromosomal instability, nor any methylation. Morphologically, these tumours were without any distinguishing features, all had tumour budding and 10 showed nuclear beta-catenin translocation. Overall, the data give an overview of the molecular classes in CRC that should be taken into account in studies on carcinogenesis and clinicopathological studies. Specifically, the absence of CIN, MSI, and CIMP in an 8.46% fraction of tumours delineates a group to be aware of.

Citing Articles

The HROC-Xenobank-A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models.

Matschos S, Burtin F, Kdimati S, Radefeldt M, Krake S, Prall F Cancers (Basel). 2021; 13(23).

PMID: 34884989 PMC: 8656526. DOI: 10.3390/cancers13235882.


Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer.

Wagner S, Beger N, Matschos S, Szymanski A, Przybylla R, Burtin F Cancers (Basel). 2021; 13(18).

PMID: 34572946 PMC: 8471446. DOI: 10.3390/cancers13184717.


High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.

Huhns M, Nurnberg S, Kandashwamy K, Maletzki C, Bauer P, Prall F Mod Pathol. 2019; 33(6):1220-1231.

PMID: 31857678 DOI: 10.1038/s41379-019-0430-6.


RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer.

Maffeis V, Nicole L, Cappellesso R Front Oncol. 2019; 9:1255.

PMID: 31803624 PMC: 6877753. DOI: 10.3389/fonc.2019.01255.


Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.

Advani S, Advani P, Brown D, DeSantis S, Korphaisarn K, VonVille H BMC Cancer. 2019; 19(1):964.

PMID: 31623592 PMC: 6796359. DOI: 10.1186/s12885-019-6144-9.